Checkpoint Therapeutics Announces $14M Equity Offering to Fund Cosibelimab Program
• Checkpoint Therapeutics announcing $14 million registered direct offering priced at-the-market
• Offering of 7,756,233 shares of common stock at $1.805 per share
• Concurrent private placement of warrants to purchase additional 7,756,233 shares
• H.C. Wainwright & Co. acting as exclusive placement agent
• Proceeds to fund planned resubmission of Biologics License Application for cosibelimab